DE68914687T2 - Hydroxamsäure enthaltende collagenase-inhibitoren. - Google Patents

Hydroxamsäure enthaltende collagenase-inhibitoren.

Info

Publication number
DE68914687T2
DE68914687T2 DE68914687T DE68914687T DE68914687T2 DE 68914687 T2 DE68914687 T2 DE 68914687T2 DE 68914687 T DE68914687 T DE 68914687T DE 68914687 T DE68914687 T DE 68914687T DE 68914687 T2 DE68914687 T2 DE 68914687T2
Authority
DE
Germany
Prior art keywords
alkyl
phenyl
group
substituted
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68914687T
Other languages
English (en)
Other versions
DE68914687D1 (de
Inventor
Colin Campion
Alan Davidson
Jonathan Dickens
Michael Crimmin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
British Bio Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Bio Technology Ltd filed Critical British Bio Technology Ltd
Application granted granted Critical
Publication of DE68914687D1 publication Critical patent/DE68914687D1/de
Publication of DE68914687T2 publication Critical patent/DE68914687T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE68914687T 1988-11-23 1989-11-23 Hydroxamsäure enthaltende collagenase-inhibitoren. Expired - Fee Related DE68914687T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888827305A GB8827305D0 (en) 1988-11-23 1988-11-23 Compounds
PCT/GB1989/001399 WO1990005719A1 (en) 1988-11-23 1989-11-23 Hydroxamic acid based collagenase inhibitors

Publications (2)

Publication Number Publication Date
DE68914687D1 DE68914687D1 (de) 1994-05-19
DE68914687T2 true DE68914687T2 (de) 1994-09-08

Family

ID=10647285

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68914687T Expired - Fee Related DE68914687T2 (de) 1988-11-23 1989-11-23 Hydroxamsäure enthaltende collagenase-inhibitoren.

Country Status (14)

Country Link
US (2) US5240958A (de)
EP (1) EP0446267B1 (de)
JP (1) JP2565599B2 (de)
AT (1) ATE104277T1 (de)
CA (1) CA2003718C (de)
DE (1) DE68914687T2 (de)
DK (1) DK175102B1 (de)
ES (1) ES2055409T3 (de)
FI (1) FI100470B (de)
GB (1) GB8827305D0 (de)
HU (1) HU211983A9 (de)
NO (1) NO177701C (de)
NZ (1) NZ231509A (de)
WO (1) WO1990005719A1 (de)

Families Citing this family (358)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
KR927003521A (ko) * 1990-12-03 1992-12-18 죤 에드워드 베리만 펩티딜(peptidyl) 유도체
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
ATE150452T1 (de) * 1992-04-07 1997-04-15 British Biotech Pharm Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9220845D0 (en) * 1992-10-03 1992-11-18 British Bio Technology Vasoactive peptide inhibition
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5326883A (en) * 1992-12-18 1994-07-05 Abbott Laboratories Oxime ether derivatives having lipoxygenase inhibitory activity
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5594006A (en) * 1993-03-18 1997-01-14 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives as matrix metalloproteinases inhibitors
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
EP0740652B1 (de) * 1994-01-20 1998-05-06 British Biotech Pharmaceuticals Limited Metalloproteinaseinhibitoren
GB9404046D0 (en) * 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
US5665753A (en) * 1994-03-03 1997-09-09 Smithkline Beecham Corporation Cytokine inhibiting imidazole substituted hydroxamic acid derivatives
GB9405076D0 (en) 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
US6140099A (en) * 1994-05-20 2000-10-31 The Trustees Of The University Of Pennsylvania Method of delaying fetal membrane rupture by inhibiting matrix metalloproteinase-9 activity
ATE182581T1 (de) * 1994-06-22 1999-08-15 British Biotech Pharm Metalloproteinase-inhibitoren
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5639746A (en) * 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5919940A (en) * 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
GB9502858D0 (en) * 1995-02-14 1995-04-05 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
AU5347896A (en) * 1995-04-26 1996-11-18 Sankyo Company Limited Beta-nonylhydroxamic acid derivatives
US6124333A (en) * 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
HUP9903863A3 (en) 1995-11-23 2000-11-28 British Biotech Pharm Metalloproteinase inhibitors
DK0780386T3 (da) * 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
AU1529897A (en) * 1996-01-02 1997-07-28 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
GB9601041D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Novel compounds
US5994351A (en) * 1998-07-27 1999-11-30 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
AU2645497A (en) * 1996-05-06 1997-11-26 Zeneca Limited Thio derivatives of hydroxamic acids
GB9609795D0 (en) * 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
US5854275A (en) * 1996-05-16 1998-12-29 Pfizer Inc. Cyclic imide derivatives
US5932579A (en) 1996-06-18 1999-08-03 Affymax Technologies N.V. Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
US5827840A (en) * 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
JP2000501423A (ja) * 1996-08-23 2000-02-08 ファイザー インク． アリールスルホニルアミノヒドロキサム酸誘導体
CN1228773A (zh) * 1996-08-28 1999-09-15 普罗克特和甘保尔公司 杂环金属蛋白酶抑制剂
SK284041B6 (sk) * 1996-08-28 2004-08-03 The Procter And Gamble Company Spirocyklická metaloproteázová inhibítorová zlúčenina a jej použitie
TR199900399T2 (xx) * 1996-08-28 1999-06-21 The Procter & Gamble Company Matris metaloproteaz inhibit�rleri olarak fosfinik asit amidleri.
NZ334254A (en) 1996-08-28 2000-11-24 Procter & Gamble Heterocyclic metalloprotease inhibitors
KR20000035918A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 1,3-디헤테로시클릭 메탈로프로테아제 저해제
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
IL128337A0 (en) 1996-09-10 2000-01-31 British Biotech Pharm Cytostatic hydroxamic acid derivatives
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
UA48262C2 (uk) * 1996-09-27 2002-08-15 Фармація Енд Апджон Компані <font face="Symbol">b</font>-СУЛЬФОНІЛ ГІДРОКСАМОВІ КИСЛОТИ ЯК ІНГІБІТОРИ МАТРИЧНИХ МЕТАЛОПРОТЕЇНАЗ, ПРОМІЖНА СПОЛУКА ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
JP2002515898A (ja) * 1997-02-25 2002-05-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ヒトの皮膚での経時老化を防止および治療するための方法および組成物
US6197791B1 (en) 1997-02-27 2001-03-06 American Cyanamid Company N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
AU750130B2 (en) * 1997-03-04 2002-07-11 Monsanto Company Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
US6476027B1 (en) 1997-03-04 2002-11-05 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
NZ503945A (en) 1997-07-31 2002-11-26 Procter & Gamble Metalloprotease-inhibiting amide derivatives
EP1042290A1 (de) 1997-11-14 2000-10-11 G.D. SEARLE &amp; CO. Eine ein aromatisches sulfon enthaltende hydroxamsäure als metalloprotease inhibitor
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
EE200000471A (et) * 1998-02-19 2002-02-15 American Cyanamid Company N-hüdroksü-2-(alküül-, arüül- või heteroarüülsulfanüül, -sulfinüül või -sulfonüül)-3-asendatud alküül-, arüül- või heteroarüülamiidid maatriksmetalloproteinaasi inhibiitoritena, meetod MMP ja TACE ensüümide toime pärssimiseks ning farmatseutiline kom
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
KR20010102000A (ko) 1999-02-08 2001-11-15 윌리암스 로저 에이 술파마토 히드록삼산 메탈로프로테아제 억제제
GB9903598D0 (en) * 1999-02-18 1999-04-07 Univ Manchester Connective tissue healing
NZ513830A (en) 1999-03-03 2001-09-28 Procter & Gamble Dihetero-substituted metalloprotease inhibitors
CZ20013176A3 (cs) 1999-03-03 2002-04-17 The Procter & Gamble Company Sloučenina vytvářející inhibitor metaloproteinasy, farmaceutický prostředek, způsob přípravy léčiva a léčivo
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
CO5210860A1 (es) 1999-10-01 2002-10-30 Hoffmann La Roche Nuevos derivados de pirimidina-2,4,6-triona
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
EP1306367B1 (de) 2000-07-19 2007-07-18 Mitsubishi Pharma Corporation Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten
CA2426013C (en) * 2000-10-24 2009-09-15 Dow Global Technologies Inc. A water-free preparation process for multimodal thermoplastic polymer foam and foam therefrom
EP1399483B1 (de) 2001-01-05 2010-04-14 Pfizer Inc. Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i
GB0100761D0 (en) * 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
CZ20032913A3 (cs) 2001-05-11 2004-05-12 Pharmaciaácorporation Aromatické sulfonhydroxamáty a jejich použití jako inhibitorů proteázy
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
US6987104B2 (en) 2001-06-15 2006-01-17 Vicuron Pharmaceuticals Inc. Pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use
US6995171B2 (en) 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
MXPA04008403A (es) 2002-03-01 2004-11-26 Pfizer Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso.
KR100984613B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
MXPA04010555A (es) 2002-04-25 2005-02-17 Pharmacia Corp Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa.
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
NZ540340A (en) 2002-12-19 2007-07-27 Pfizer 2-(1H-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
OA13151A (en) 2003-02-26 2006-12-13 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors.
DK1610678T3 (da) 2003-04-04 2011-10-24 Yeda Res & Dev Antistoffer til inhibering af aktiviteten af MMP-2 og MMP-9
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
MXPA06002296A (es) 2003-08-29 2006-05-22 Pfizer Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP1689387B1 (de) 2003-11-19 2011-09-14 Array Biopharma, Inc. Bicyclische inhibitoren von mek und verfahren zu deren herstellung
DK1689721T3 (da) * 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazolderivater som GSK-3-ihibitorer
US7534918B2 (en) * 2004-07-12 2009-05-19 Merck & Co., Inc. Histone deacetylase inhibitors
WO2006008639A1 (en) 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
WO2006021884A2 (en) 2004-08-26 2006-03-02 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
ES2405785T3 (es) 2005-05-18 2013-06-03 Array Biopharma Inc. Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
ATE533057T1 (de) 2005-09-20 2011-11-15 Osi Pharm Inc Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
WO2007121269A2 (en) 2006-04-11 2007-10-25 Ardea Biosciences, Inc. N-aryl-n'alkyl sulfamides as mek inhibitors
DE602007009663D1 (de) 2006-04-18 2010-11-18 Ardea Biosciences Inc Pyridonsulfonamide und pyridonsulfamide als mek-hemmer
US7713541B1 (en) 2006-11-21 2010-05-11 Abbott Cardiovascular Systems Inc. Zwitterionic terpolymers, method of making and use on medical devices
CA2672815A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives for use in treating abnormal cell growth
AU2008206045A1 (en) 2007-01-19 2008-07-24 Ardea Biosciences, Inc. Inhibitors of MEK
MX2009008914A (es) 2007-02-23 2009-08-28 Yeda Res & Dev Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas.
CN101678215B (zh) 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
CA2694646C (en) 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
RU2441004C1 (ru) 2007-12-19 2012-01-27 Дженентек, Инк. 5-анилиноимидазопиридины и способы их применения
CA2708176A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009204483B2 (en) 2008-01-04 2014-03-13 Intellikine, Llc Certain chemical entities, compositions and methods
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
WO2009121039A2 (en) 2008-03-28 2009-10-01 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US8895546B2 (en) 2009-03-27 2014-11-25 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
US8476410B2 (en) 2008-10-16 2013-07-02 University of Pittsburgh—of the Commonwealth System of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
SG10201706294VA (en) 2009-02-05 2017-09-28 Immunogen Inc Novel benzodiazepine derivatives
EP2393814A1 (de) 2009-02-09 2011-12-14 SuperGen, Inc. Pyrrolopyrimidinylverbindungen als axl-kinase-inhibitoren
EP2400985A2 (de) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Kombination eines anti-igf-1r-antikörpers oder eines igf-bindungsproteins und eines kleinmoleküligen igf-1r-kinase-inhibitors
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
EP2401613A2 (de) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (de) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
ES2543608T3 (es) 2009-03-27 2015-08-20 Ardea Biosciences, Inc. Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de MEK
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
WO2011014726A1 (en) 2009-07-31 2011-02-03 Osi Pharmaceuticals, Inc. Mtor inhibitor and angiogenesis inhibitor combination therapy
CA2771532C (en) 2009-08-17 2021-03-23 Intellikine, Inc. Heterocyclic compounds and uses thereof
EP2473500A2 (de) 2009-09-01 2012-07-11 Pfizer Inc. Benzimidazolderivate
CA2814617C (en) 2009-10-13 2017-12-19 Allostem Therapeutics Llc Novel mek inhibitors, useful in the treatment of diseases
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
KR102012398B1 (ko) 2009-11-05 2019-08-20 리젠 파마슈티컬스 소시에떼 아노님 신규한 벤조피란 키나제 조절제
AU2011210362B2 (en) 2010-01-27 2015-09-10 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
CN102933231B (zh) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20抗体及其用途
DK3150610T3 (da) 2010-02-12 2019-11-04 Pfizer Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on
JP2013527748A (ja) 2010-03-03 2013-07-04 オーエスアイ・ファーマシューティカルズ，エルエルシー インスリン様増殖因子１受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
IT1401253B1 (it) 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
KR101871436B1 (ko) 2010-05-17 2018-06-27 인코젠 쎄라퓨틱스 프라이빗 리미티드 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3ｈ-이미다조[4,5-ｂ]피리딘 및 3,5- 디치환 -3ｈ-[1,2,3]트리아졸로[4,5-ｂ] 피리딘 화합물
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
EP3135692B8 (de) 2010-06-16 2019-03-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Antikörper zu endoplasmin und deren verwendung
CA2813162C (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2- derivatives as smoothened receptor modulators
EP2632956B1 (de) 2010-10-28 2018-06-20 Yeda Research and Development Co. Ltd. Verfahren zur erzeugung von antikörpern gegen metalloenzyme
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
BR112013017670B1 (pt) 2011-01-10 2022-07-19 Infinity Pharmaceuticals, Inc Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
KR20140010067A (ko) 2011-02-15 2014-01-23 이뮤노젠 아이엔씨 컨쥬게이트의 제조방법
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
CA3019531A1 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
EP2702173A1 (de) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Verwendung von emt-gensignaturen bei der entdeckung von krebswirkstoffen, -diagnostika und -behandlungen
MX365160B (es) 2011-05-04 2019-05-24 Rhizen Pharmaceuticals Sa Compuestos novedosos como moduladores de proteína cinasas.
KR20140063605A (ko) 2011-07-19 2014-05-27 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013013188A1 (en) 2011-07-21 2013-01-24 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
MD20140023A2 (ro) 2011-09-22 2014-06-30 Pfizer Inc. Derivaţi de pirolpirimidină şi purină
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
EP2764025B1 (de) 2011-10-04 2017-11-29 IGEM Therapeutics Limited Ige-antikörper gegen hmw-maa
RU2014114015A (ru) 2011-11-08 2015-12-20 Пфайзер Инк. Способы лечения воспалительных расстройств с использованием антител против m-csf
US9452215B2 (en) 2012-02-22 2016-09-27 The Regents Of The University Of Colorado Bourvadin derivatives and therapeutic uses thereof
EP2817004B1 (de) 2012-02-22 2018-04-11 The Regents of The University of Colorado, A Body Corporate Bouvardin-derivate und therapeutische verwendung davon
SG11201406185WA (en) 2012-03-30 2014-11-27 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
ES2718478T3 (es) 2012-06-08 2019-07-02 Sutro Biopharma Inc Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
AU2013308494B2 (en) 2012-08-31 2018-03-01 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
US9394257B2 (en) 2012-10-16 2016-07-19 Tolero Pharmaceuticals, Inc. PKM2 modulators and methods for their use
EP2914296B2 (de) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Behandlung von krebs mit pi3-kinase-isoformmodulatoren
US9901647B2 (en) 2013-02-28 2018-02-27 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
JP6494533B2 (ja) 2013-02-28 2019-04-03 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
CN105308033B (zh) 2013-03-14 2018-08-24 特雷罗药物股份有限公司 Jak2和alk2抑制剂及其使用方法
US20160024051A1 (en) 2013-03-15 2016-01-28 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
TW201524952A (zh) 2013-03-15 2015-07-01 Araxes Pharma Llc Ｋｒａｓ ｇ１２ｃ之共價抑制劑
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
HUE036600T2 (hu) 2013-10-03 2018-07-30 Kura Oncology Inc ERK inhibitorok és alkalmazási eljárások
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
ES2900806T3 (es) 2013-10-04 2022-03-18 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
UA119971C2 (uk) 2013-10-10 2019-09-10 Араксіс Фарма Ллк Інгібітори g12c kras
EP3055298B1 (de) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
NZ725496A (en) 2014-04-30 2019-11-29 Pfizer Cycloalkyl-linked diheterocycle derivatives
DK3157916T3 (en) 2014-06-19 2019-03-18 Ariad Pharma Inc HETEROARYL COMPOUNDS FOR CHINESE INHIBITION
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
CN106999578B (zh) 2014-07-31 2022-03-04 美国政府(由卫生和人类服务部的部长所代表) 针对epha4的人类单克隆抗体和其用途
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JP2017528498A (ja) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
WO2016097918A1 (en) 2014-12-18 2016-06-23 Pfizer Inc. Pyrimidine and triazine derivatives and their use as axl inhibitors
US10246424B2 (en) 2015-04-10 2019-04-02 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
ES2856880T3 (es) 2015-04-15 2021-09-28 Araxes Pharma Llc Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
MX2017013383A (es) 2015-04-20 2017-12-07 Tolero Pharmaceuticals Inc Prediccion de respuesta a alvocidib mediante perfilado mitocondrial.
MX2017013956A (es) 2015-05-01 2018-09-05 Cocrystal Pharma Inc Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer.
EP3298021B1 (de) 2015-05-18 2019-05-01 Tolero Pharmaceuticals, Inc. Alvocidib-prodrugs mit erhöhter bioverfügbarkeit
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
AU2016301315C1 (en) 2015-08-03 2022-07-07 Sumitomo Pharma Oncology, Inc. Combination therapies for treatment of cancer
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356359B1 (de) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
EP3356349A1 (de) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3364977A4 (de) 2015-10-19 2019-09-04 Araxes Pharma LLC Verfahren zum screening von inhibitoren von ras
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
AU2016364855B2 (en) 2015-12-03 2019-08-29 Les Laboratoires Servier MAT2A inhibitors for treating MTAP null cancer
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
KR20180104106A (ko) 2016-01-27 2018-09-19 서트로 바이오파마, 인크. anti-CD74 항체 접합체, anti-CD74 항체 접합체를 포함하는 조성물 및 anti-CD74 항체 접합체의 이용 방법
MA43823A (fr) 2016-03-16 2018-11-28 Kura Oncology Inc Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation
IL261606B (en) 2016-03-16 2022-09-01 Kura Oncology Inc Inhibitors of converted menin-mll and methods of use
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
EP3454945B1 (de) 2016-05-12 2022-01-19 The Regents Of The University Of Michigan Ash11-inhibitoren und verfahren zur behandlung damit
US11118233B2 (en) 2016-05-18 2021-09-14 The University Of Chicago BTK mutation and ibrutinib resistance
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
AU2017321973A1 (en) 2016-09-02 2019-03-07 Dana-Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders
EP3519402A1 (de) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
KR20190099260A (ko) 2016-12-19 2019-08-26 톨레로 파마수티컬스, 인크. 프로파일링 펩티드 및 감도 프로파일링을 위한 방법
JOP20190154B1 (ar) 2016-12-22 2022-09-15 Amgen Inc بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم
EP3573967A1 (de) 2017-01-26 2019-12-04 Araxes Pharma LLC Kondensierte bicyclische hetero-hetero-verbindungen und verfahren zur verwendung davon
US20200385364A1 (en) 2017-01-26 2020-12-10 Araxes Pharma Llc Fused n-heterocyclic compounds and methods of use thereof
EP3573971A1 (de) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-on-derivate und ähnliche verbindungen als kras-g12c-modulatoren zur behandlung von krebs
EP3573970A1 (de) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalin-1-yl)chinazolin-2-yl)azetidin-1-yl)prop-2-en-1-on-derivate und ähnliche verbindungen wie kras g12c-inhibitoren zur behandlung von krebs
EP3573964A1 (de) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophen- und benzothiazolverbindungen und verfahren zur verwendung davon
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11267885B2 (en) 2017-01-26 2022-03-08 Zlip Holding Limited CD47 antigen binding unit and uses thereof
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CA3063440A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
EP3658588A1 (de) 2017-07-26 2020-06-03 Sutro Biopharma, Inc. Verfahren zur verwendung von anti-cd74-antikörpern und antikörperkonjugaten bei der behandlung von t-zell-lymphomen
ES2928576T3 (es) 2017-09-08 2022-11-21 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
JP7423513B2 (ja) 2017-09-18 2024-01-29 ストロ バイオファーマ インコーポレーテッド 抗葉酸受容体α抗体コンジュゲート及びその使用
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
US20200237766A1 (en) 2017-10-13 2020-07-30 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer
JP7424637B2 (ja) 2017-11-10 2024-01-30 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ａｓｈ１ｌ分解剤及びそれを用いた治療方法
US11324729B2 (en) 2017-12-07 2022-05-10 The Regents Of The University Of Michigan NSD family inhibitors and methods of treatment therewith
CN112533602A (zh) 2018-04-05 2021-03-19 大日本住友制药肿瘤公司 Axl激酶抑制剂及其用途
MA52496A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
MX2020011907A (es) 2018-05-10 2021-01-29 Amgen Inc Inhibidores de kras g12c para el tratamiento de cancer.
CA3098885A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP3813784B1 (de) 2018-06-07 2024-01-10 The Regents Of The University Of Michigan Prc1-inhibitoren und prc1-inhibitoren zur verwendung in verfahren zur behandlung damit
EP3802537A1 (de) 2018-06-11 2021-04-14 Amgen Inc. Kras-g12c-inhibitoren zur behandlung von krebs
JP7369719B2 (ja) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
CN112512597A (zh) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
AU2019312670A1 (en) 2018-08-01 2021-02-04 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
US20220047716A1 (en) 2018-09-17 2022-02-17 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
BR112021006407A8 (pt) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med uso de inibidores do egfr para ceratodermas
KR20210083286A (ko) 2018-10-24 2021-07-06 아락세스 파마 엘엘씨 종양 전이를 억제하기 위한 g12c 돌연변이 kras 단백질의 억제제로서 2-(2-아크릴로일-2,6-디아자스피로[3.4]옥탄-6-일)-6-(1h-인다졸-4-일)-벤조니트릴 유도체 및 관련 화합물
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CA3117222A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP2022509830A (ja) 2018-11-29 2022-01-24 アラクセス ファーマ エルエルシー がんを処置するための化合物およびその使用方法
AU2019391097A1 (en) 2018-12-04 2021-05-20 Sumitomo Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
CA3123044A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
MA54543A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
MX2021007104A (es) 2018-12-20 2021-08-11 Amgen Inc Inhibidores de kif18a.
JP2022513967A (ja) 2018-12-20 2022-02-09 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
IL264768A (en) 2019-02-10 2020-08-31 Sagi Irit ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) inhibitory antibody and its use
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN113767100A (zh) 2019-03-01 2021-12-07 锐新医药公司 双环杂芳基化合物及其用途
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
EP3941463A1 (de) 2019-03-22 2022-01-26 Sumitomo Dainippon Pharma Oncology, Inc. Zusammensetzungen mit pkm2-modulatoren und behandlungsverfahren damit
US20220362394A1 (en) 2019-05-03 2022-11-17 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
EP3738593A1 (de) 2019-05-14 2020-11-18 Amgen, Inc Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
CN114144414A (zh) 2019-05-21 2022-03-04 美国安进公司 固态形式
KR20220028075A (ko) 2019-07-03 2022-03-08 스미토모 다이니폰 파마 온콜로지, 인크. 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
JP2022542392A (ja) 2019-08-02 2022-10-03 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤としてのピリジン誘導体
AU2020324963A1 (en) 2019-08-02 2022-02-24 Amgen Inc. KIF18A inhibitors
CN114302880A (zh) 2019-08-02 2022-04-08 美国安进公司 Kif18a抑制剂
CA3147272A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
US20220402916A1 (en) 2019-09-18 2022-12-22 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
WO2021067215A1 (en) 2019-09-30 2021-04-08 Agios Pharmaceuticals, Inc. Piperidine compounds as menin inhibitors
MX2022004656A (es) 2019-10-24 2022-05-25 Amgen Inc Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
EP4051678A1 (de) 2019-10-28 2022-09-07 Merck Sharp & Dohme Corp. Kleinmolekülige inhibitoren der kras-g12c-mutante
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
JP2022553859A (ja) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
BR112022008565A2 (pt) 2019-11-04 2022-08-09 Revolution Medicines Inc Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras
TW202132315A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ras 抑制劑
CN114901662A (zh) 2019-11-08 2022-08-12 锐新医药公司 双环杂芳基化合物及其用途
MX2022005708A (es) 2019-11-14 2022-06-08 Amgen Inc Sintesis mejorada del compuesto inhibidor de g12c de kras.
MX2022005726A (es) 2019-11-14 2022-06-09 Amgen Inc Sintesis mejorada del compuesto inhibidor de g12c de kras.
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
JP2023509701A (ja) 2020-01-07 2023-03-09 レヴォリューション・メディスンズ，インコーポレイテッド Ｓｈｐ２阻害剤投薬およびがんを処置する方法
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
WO2021207310A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
TW202204333A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
EP4139299A1 (de) 2020-04-24 2023-03-01 Taiho Pharmaceutical Co., Ltd. Kras-g12d-proteinhemmer
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
CN116113406A (zh) 2020-07-10 2023-05-12 密歇根大学董事会 Gas41抑制剂及其使用方法
WO2022014640A1 (ja) 2020-07-15 2022-01-20 大鵬薬品工業株式会社 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
EP4208261A1 (de) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Verwendung von sos1-inhibitoren zur behandlung von malignitäten mit shp2-mutationen
EP4214209A1 (de) 2020-09-15 2023-07-26 Revolution Medicines, Inc. Indolderivate als ras-inhibitoren bei der behandlung von krebs
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
AR124449A1 (es) 2020-12-22 2023-03-29 Qilu Regor Therapeutics Inc Inhibidores de sos1 y usos de los mismos
US20220363696A1 (en) 2021-04-13 2022-11-17 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
JP2024519205A (ja) 2021-04-30 2024-05-09 セルジーン コーポレーション 抗ｂｃｍａ抗体薬物コンジュゲート（ａｄｃ）をガンマセクレターゼ阻害剤（ｇｓｉ）と組み合わせて使用する併用療法
CN117616031A (zh) 2021-05-05 2024-02-27 锐新医药公司 用于治疗癌症的ras抑制剂
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
EP4334321A1 (de) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras-inhibitoren
EP4347041A1 (de) 2021-05-28 2024-04-10 Taiho Pharmaceutical Co., Ltd. Kleinmolekülige inhibitoren von kras-mutierten proteinen
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (de) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazinverbindungen als shp2-inhibitoren
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023211812A1 (en) 2022-04-25 2023-11-02 Nested Therapeutics, Inc. Heterocyclic derivatives as mitogen-activated protein kinase (mek) inhibitors
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024006542A1 (en) 2022-06-30 2024-01-04 Sutro Biopharma, Inc. Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
WO2024010925A2 (en) 2022-07-08 2024-01-11 Nested Therapeutics, Inc. Mitogen-activated protein kinase (mek) inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105789A (en) * 1976-05-10 1978-08-08 E. R. Squibb & Sons, Inc. Carboxyalkylacylamino acids
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4496540A (en) * 1982-12-30 1985-01-29 Biomeasure, Inc. Therapeutic compounds
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes

Also Published As

Publication number Publication date
GB8827305D0 (en) 1988-12-29
EP0446267A1 (de) 1991-09-18
CA2003718C (en) 1998-06-16
HU211983A9 (en) 1996-01-29
DK175102B1 (da) 2004-06-01
DK96691D0 (da) 1991-05-22
AU644064B2 (en) 1993-12-02
EP0446267B1 (de) 1994-04-13
ATE104277T1 (de) 1994-04-15
DE68914687D1 (de) 1994-05-19
ES2055409T3 (es) 1994-08-16
NO911962L (no) 1991-07-08
US5310763A (en) 1994-05-10
JPH04502008A (ja) 1992-04-09
NZ231509A (en) 1992-06-25
WO1990005719A1 (en) 1990-05-31
NO177701C (no) 1995-11-08
FI912491A0 (fi) 1991-05-22
CA2003718A1 (en) 1990-05-23
DK96691A (da) 1991-07-23
NO177701B (no) 1995-07-31
NO911962D0 (no) 1991-05-22
FI100470B (fi) 1997-12-15
JP2565599B2 (ja) 1996-12-18
US5240958A (en) 1993-08-31
AU4800390A (en) 1990-06-12

Similar Documents

Publication Publication Date Title
DE68914687D1 (de) Hydroxamsäure enthaltende collagenase-inhibitoren.
FI954351A (fi) Hydroksaamihappojohdannaiset metalloproteinaasi-inhibiittoreina
KR927003624A (ko) 화합물
DE69103636D1 (de) Biaromatische verbindungen und ihre anwendung in menschen- und tierheilkunde und in der kosmetik.
DE69309047D1 (de) Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
ATE279391T1 (de) Anti-imflammtorische indolderivate
ATE133658T1 (de) Aromatische verbindungen diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische verwendung
ATE297375T1 (de) Pharmazeutische verbindungen
YU32100A (sh) Derivati hidrosamske kiseline kao inhibitori matrične metaloproteaze (mmp)
DE69718634T2 (de) Hydroxamsäurederivate zur verwendung in der behandlung von bindegewebserkrankungen
DE59607208D1 (de) Verwendung eines Natrium- oder Lysiniumsalzes von Crotonsäureamidderivaten zur Herstellung eines Arzneimittels zur Behandlung von Krebserkrankungen
FI955429A (fi) 1-aryylisykloalkyylisulfideja, sulfoksideja ja sulfoneja depression, tuskatilojen ja Parkinsonin taudin hoitamiseksi
KR880009003A (ko) 5-(3-알킬-5-3급 부틸-4-히드록시페닐)-2-아미노-6h-1,3,4-티아디아진, 이의 제조방법, 이를 포함하는 약제 및 이의 용도
DE69808326D1 (de) Azetidinonderivate zur behandlung von hcmv entzündungen
ATE157650T1 (de) Carbamoylhydroxylamine and deren verwendung in der polymerchemie
DE3861545D1 (de) Aminoverbindungen und diese enthaltende fungizide.
ATE179890T1 (de) Verwendung von benzothiophenen zur herstellung eines medikaments zur verminderung der narbenbildung bei der wundheilung
FI952205A0 (fi) Terapeuttisia aineita

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8315 Request for restriction filed
8318 Patent restricted
8339 Ceased/non-payment of the annual fee